SCHEMBL5550139

SCHEMBL5550139

COC(=O)c1cc2c(Oc3ccccc3-c3ccccc3)cncc2s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNC P24863 4/20 0.61
▸ CDK8 P49336 4/20 0.61
▸ MAP3K8 P41279 4/20 0.60
▸ ICAM1 P05362 10/20 0.58
▸ SELE P16581 10/20 0.58
▸ VCAM1 P19320 5/20 0.58
▸ CSNK1D P48730 3/20 0.57
▸ GSK3A P49840 3/20 0.57
▸ GSK3B P49841 3/20 0.57
▸ DYRK1A Q13627 3/20 0.57
▸ AURKB Q96GD4 3/20 0.57
▸ RPS6KB1 P23443 2/20 0.57
▸ NTRK2 Q16620 1/20 0.57
▸ PLK4 O00444 2/20 0.56
▸ AURKA O14965 2/20 0.56
▸ DAPK3 O43293 2/20 0.56
▸ CHEK2 O96017 2/20 0.56
▸ CDK1 P06493 2/20 0.56
▸ PIM1 P11309 2/20 0.56
▸ PRKACA P17612 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7060310 0.85 GSK3A (0.78) CCNCCDK8MAP3K8ICAM1SELE
SCHEMBL7056414 0.84 CCNC (0.64) CCNCCDK8MAP3K8ICAM1SELE
SCHEMBL5550142 0.79 CSNK1D (0.46) CCNCCDK8MAP3K8ICAM1SELE
SCHEMBL7059462 0.78 CCNC (0.56) CCNCCDK8MAP3K8ICAM1SELE
SCHEMBL7052261 0.77 CCNC (0.57) CCNCCDK8MAP3K8ICAM1SELE
SCHEMBL7053786 0.77 CCNC (0.77) CCNCCDK8MAP3K8ICAM1SELE
SCHEMBL7054426 0.77 CCNC (0.80) CCNCCDK8MAP3K8ICAM1SELE
SCHEMBL7058294 0.76 ICAM1 (0.78) CCNCCDK8MAP3K8ICAM1SELE
SCHEMBL5555774 0.76 MAP3K8 (0.80) CCNCCDK8MAP3K8ICAM1SELE
SCHEMBL7057140 0.76 CDK8 (1.00) CCNCCDK8MAP3K8ICAM1SELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753428-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2007-02-21 — — EP disclosed
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABBOTT LABORATORIES 2006-04-06 — — US disclosed
WO-2005110410-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABL1, MAP3K19, MAP3K20 CCNC 981/4885CDK8 181/4885MAP3K8 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback